From recurrence monitoring to treatment response: MRD data insights across the cancer care continuum

Luis E. Raez, MD, is the Chief Scientific Officer and Medical Director of the Memorial Cancer Institute (MCI). He leads the MCI/FAU Florida Cancer Center of Excellence and the Thoracic Oncology Program, bringing world-class expertise to lung cancer treatment and liquid biopsy research. With a distinguished academic background including professorships at FIU, FAU, and Cayetano Heredia University, Dr. Raez is a past President of the Florida Society of Clinical Oncology (FLASCO). He previously served for ten years at the Sylvester Cancer Center/University of Miami and remains a leading voice in addressing cancer disparities.

Dr. Peter A. Prieto is the Senior Vice President of Medical Affairs at Tempus AI, where he leads strategic initiatives in artificial intelligence, digital pathology, and molecular diagnostics. A quadruple board-certified surgical oncologist and tumor immunotherapist, Dr. Prieto advocates for integrating multimodal data and AI-driven models into clinical workflows to advance precision oncology.

Prior to Tempus, Dr. Prieto served as Senior Vice President of Medical Affairs at Iovance Biotherapeutics. There, he built a global medical affairs organization and led the successful launch of Amtagvi, a first-in-class TIL therapy for metastatic melanoma. His clinical background includes a residency at Yale University School of Medicine and a three-year fellowship at the National Cancer Institute under Dr. Steven A. Rosenberg, where he co-investigated pioneering adoptive cell therapy trials.

Alan Tan, MD, serves as the Vice President of Research and Clinical Strategy at Tempus and is an Associate Professor and GU Medical Oncologist at Vanderbilt-Ingram Cancer Center in Nashville, TN.

With a clinical practice dedicated to bladder cancer, renal cell carcinoma, and prostate cancer, Dr. Tan’s research focuses on the intersection of biomarker development and treatment de-escalation strategies. A recognized leader in precision oncology, he has served as the senior author on several key publications in the ctDNA and MRD space, contributing to the evolving landscape of liquid biopsies and minimal residual disease monitoring to improve patient outcomes.  He previously served as GU Executive Officer at the NCI cooperative Alliance for Clinical Trials in Oncology.

Dr. Sanjay Juneja is a triple board-certified hematologist and medical oncologist serving as Vice President of Clinical AI Operations at Tempus AI. In this role, he leads strategies to integrate artificial intelligence into real-world oncology. He maintains an active practice with Citrus Oncology and serves on the Editorial Board of AI in Precision Oncology. A Louisiana native and LSU Honors College alumnus, Dr. Juneja has received prestigious honors, including being named Targeted Oncology’s 2024 Oncology Icon and attending the White House’s 2023 Healthcare Leaders in Social Media Roundtable. As founder of TensorBlack Inc., his expertise is frequently featured in The Washington Post and WIRED. Known globally as "TheOncDoc," he reaches over 750,000 professionals, using his platform and podcast to translate complex AI concepts for practitioners in over 100 countries.